Source comparison
BPC-157 Studied Crohn's Disease Research: Trial Comparison
TNBS-induced colitis (2019) 87% fistula closure at 14 days 30–50% with anti-TNF biologics VEGF upregulation, accelerated granulation Strongest preclinical signal for fistula healing. No human trial data yet DSS-induced colitis (2021) 72% DAI reduction 45% with
This comparison does not assign a generated winner or score.
- TNBS-induced colitis (2019)
- 87% fistula closure at 14 days
- 30–50% with anti-TNF biologics
- VEGF upregulation, accelerated granulation
- Strongest preclinical signal for fistula healing. No human trial data yet
- DSS-induced colitis (2021)
- 72% DAI reduction
- 45% with mesalamine, 58% with prednisolone
- TNF-α/IL-6 suppression without systemic immunosuppression
- Comparable anti-inflammatory effect to steroids but different toxicity profile
- Acetic acid injury model (2020)
- 68% macroscopic damage reduction
- 40% with budesonide
- NO pathway modulation (eNOS↑ 240%, iNOS↓ 65%)
- Unique dual effect on NO. Promotes healing while reducing inflammatory NO
- Gut barrier permeability study (2020)
- TEER restored to 85% of normal
- 50% with budesonide
- Tight junction protein upregulation (claudin-1, occludin, ZO-1)
- Directly repairs barrier. Not just symptom control but structural restoration